Alibaba Health Shares Climb Amid Optimism Over AI Use in Healthcare
By Jason Chau
Shares of Alibaba's healthcare arm notched another day of double-digit gains, benefiting from investor optimism that it is well-placed to benefit from the use of AI in the sector.
Alibaba Health Information Technology's stock closed 19% higher in Hong Kong on Wednesday, on track for its best monthly performance since February last year.
Analysts say the gains are linked to the broader rally in artificial intelligence-linked stocks, noting that AliHealth's ties to parent Alibaba put it in prime position to cash in on AI adoption in China's healthcare industry.
"AliHealth has dominant traffic advantage and partnership opportunities with sister companies, as well as strength in AI development," Citi analysts said in a note, expecting a strong year ahead for the company.
For example, Alibaba affiliate Ant Group has recently launched a digital health consultation app that may offer some traffic benefits to other group companies, even though they are separate entities that operate independently, said Cui Cui, Jefferies's head of Asia healthcare research.
AliHealth is UOB Kay Hian's top pick in the sector, analysts Carol Dou and Sunny Chen wrote in a note. They cited tailwinds including strong earnings growth, improving operating efficiency with AI adoption, integration with Alibaba's marketing business, and attractive valuations.
Shares of AliHealth parent Alibaba Group ended the day 5.7% higher.
Write to Jason Chau at jason.chau@wsj.com
(END) Dow Jones Newswires
January 14, 2026 04:13 ET (09:13 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
